StudyFinder

MT2020-34: A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to < 18 years of age) with Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation (HSCT)

Recruiting

To assess the efficacy of ravulizumab plus BSC in the treatment of pediatric participants with HSCT-TMA.

I'm interested

This study is NOT accepting healthy volunteers

Thrombotic Microangiopathy

Hematopoietic Stem Cell Transplant, Ravulizumab, Thrombotic Microangiopathy (TMA), Ultomiris

Kim Nelson - knelso62@fairview.org
Jessica Knight-Perry
Phase III
STUDY00011217
NCT04557735
See this study on ClinicalTrials.gov

Back